Digitalization is on the rise of the pharmaceutical industry, and domestic and foreign pharmaceutical companies are accelerating their deployment

With the development of cloud computing, 5G, Internet, big data and other technologies, a large number of pharmaceutical companies are building core competitiveness
through digitalization, big data and AI.
It is worth noting that at the same time, cooperation with digital enterprises and platforms has also begun to increase
.
On October 27, XtalPi announced a research collaboration with Janssen Pharmaceuticals ("Janssen"), a subsidiary of Johnson & Johnson, to provide Janssen with new structural compound design, screening, and synthesis services
.
The research protocol is led
by Johnson & Johnson Innovations.
Under the agreement, XtalPi will provide small molecule active molecules
with characteristic specifications for specific targets specified by Janssen.
XtalPi will deploy its comprehensive end-to-end platform, inclusive digital drug discovery and development, which includes proprietary cloud-based computing and advanced wet lab capabilities designed to shorten the design-make-test-analyze (DMTA) cycle
.
Coincidentally, on October 24, Salubris also signed a cooperation agreement
with Alpha Molecule to jointly develop new drugs.
According to the agreement, the cooperation between Salubris and Alpha Molecule combines Salubris' drug discovery, development and clinical transformation capabilities with Alpha Molecule's biocomputing, AI and original biotechnology, further improving the efficiency and success rate of new drug research and development, promoting the industrialization and upgrading of both parties in the international and domestic markets, accelerating the discovery of drug molecules with potential anti-obesity targets, and achieving a win-win situation
in the field of new drug research and development.
With the help of artificial intelligence, digitalization, and artificial intelligence to accelerate innovation and research and development, it is not surprising
that it has long been in the pharmaceutical track.
Since 2022, many domestic and foreign pharmaceutical companies have announced that they will cooperate with technology companies and artificial intelligence platforms to accelerate the development of new drugs
.
On October 18, GSK announced an expanded three-year collaboration agreement with U.
S.
precision medicine company Tempus, under which GSK will have access to Tempus' artificial intelligence platform, including data
that identifies patients and their situations.
On August 9, Antengene announced that it has reached a long-term strategic cooperation with AI drug development company DeRich to jointly promote the research and development
of the first innovative small molecule anti-tumor drug.
It is worth mentioning that some time ago, DeGene has contributed
to the development of a preclinical drug candidate of Antengene.
In May, Biogen and MedRhythms announced an R&D collaboration to jointly develop MedRhythms' investigational prescription digital therapeutics MR-004 for the treatment of gait disorders in patients with multiple sclerosis (MS).
.
.
In general, digitalization and intelligence are increasingly becoming emerging forces in the transformation and upgrading of China's medical system, and the integration and innovation with the pharmaceutical industry has gradually become a new trend
in the current industrial development.
At present, major pharmaceutical companies are increasing their investment in digital construction, and it is reported that in 2019, digitalization-related expenses accounted for 23% of the total product investment cost of pharmaceutical companies with more than 10%.

In the future, with the continuous development of the innovative drug industry, the industry expects that pharmaceutical companies will continue to increase
their investment and layout in digitalization and AI.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.